Sphingosine pathway modulating compounds for the treatment of cancers
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
1. A method for treating a leukemia in a mammalian subject, comprising the step of:
coadministering to a mammalian subject in need of treatment for a leukemia a therapeutically effective amount of:
(i) ozanimod or a pharmaceutically acceptable salt thereof, and
(ii) the compound
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the mammalian subject is a human.
3. The method of claim 1 , wherein the leukemia is Acute lymphoblastic leukemia (ALL).
4. The method of claim 3 , wherein the mammalian subject is a human.
5. The method of claim 1 , wherein the hydrochloride salt of ozanimod is coadministered.
6. The method of claim 5 , wherein the hydrochloride salt of the compound
is coadministered.
7. The method of claim 1 , wherein the hydrochloride salt of the compound
is coadministered.
8. The method of claim 2 , wherein the hydrochloride salt of ozanimod is coadministered.
9. The method of claim 8 , wherein the hydrochloride salt of the compound
is coadministered.
10. The method of claim 2 , wherein the hydrochloride salt of the compound
is coadministered.
11. The method of claim 3 , wherein the hydrochloride salt of ozanimod is coadministered.
12. The method of claim 11 , wherein the hydrochloride salt of the compound
is coadministered.
13. The method of claim 3 , wherein the hydrochloride salt of the compound
is coadministered.
14. The method of claim 4 , wherein the hydrochloride salt of ozanimod is coadministered.
15. The method of claim 14 , wherein the hydrochloride salt of the compound
is coadministered.
16. The method of claim 4 , wherein the hydrochloride salt of the compound
is coadministered.